| Cat. No. |
Product Name |
Information |
| PC-22992 |
Y06014
BET inhibitor
|
Y06014 is a selective BRD4(1) inhibitor with IC50 of 4.87 uM. |
| PC-22925 |
GSK2801
BAZ2A/B inhibitor
|
GSK2801 is a potent, selective and cell active acetyl-lysine competitive inhibitor of BAZ2A and BAZ2B bromodomains with KD values of 136 and 257 nM for BAZ2B and BAZ2A, respectively. |
| PC-22528 |
I-BET469
BET inhibitor
|
I-BET469 is a potent, selective pan-BET bromodomain inhibitor with pIC50 of 7.9 for BRD4 BD1, >5000-fold selective over BAZ2A. |
| PC-22527 |
I-BET787
BET inhibitor
|
I-BET787 (GSK3535787) is potent, efficient pan-BET bromodomain inhibitor with pIC50 of 7.1/5.9 for BRD4 BD1/BD2, respectively. |
| PC-22485 |
Y08284
CBP/p300 inhibitor
|
Y08284 is a potent, selective CBP/p300 bromodomain inhibitor with IC50 of 4.21 nM (CBP bromodomain) in HTRF assays. |
| PC-22484 |
Y08207
CBP/p300 inhibitor
|
Y08207 is a potent, selective CBP/p300 bromodomain inhibitor with IC50 of 26.37 nM (CBP bromodomain) in HTRF assays. |
| PC-22483 |
Y08262
CBP/p300 inhibitor
|
Y08207 is a potent, selective CBP/p300 bromodomain inhibitor with IC50 of 73.1 nM (CBP bromodomain) in HTRF assays. |
| PC-22287 |
CDD-1302
BRDT BD2 inhibitor
|
CDD-1302 (CDD1302) is a potent, selective second bromodomain (BD2) of BRDT and BRD4 inhibitor with IC50 of 8 and 12 nM, >1,000-fold and 300-fold selectivity over BRDT-BD1 and BRD4-BD1. |
| PC-22217 |
Rac EBET-590
BET inhibitor
|
Rac EBET-590 (EBET-590 Racemate) is a small molecule BET inhibitor. |
| PC-22216 |
EBET-590
BET inhibitor
|
EBET-590 (ER-001251206-000) is a small molecule BET inhibitor. |
| PC-22204 |
SDU-071
BRD4-p53 inhibitor
|
SDU-071 is a potent small molecule BRD4-p53 PPI inhibitor with IC50 of 2.7 uM, reduces the expression of BRD4-regulated genes, such as c-Myc and Mucin 5AC, and induces cell cycle arrest and apoptosis. |
| PC-22158 |
BBC0403
BRD2 inhibitor
|
BBC0403 (BBC-0403) is a specific BRD2 inhibitor with binding Kd of 41.4 uM and 7.6 uM for BRD2 (BD1) and BRD2 (BD2), inhibits the NF-κB and MAPK signalling pathways and the progression of osteoarthritis pathogenesis. |
